2012, № 12 (148)

1. Astakhov Yu.S., Lisochkina A.B., Shadrichev F.E. Age-related macular degeneration. Clinical recommendations. Ophthalmology / Edited by L.K. moshetova, A.P. Nesterov, E.A.Egorov.– М.: GEOTAR-Media, 2006. — P. 164-188.

2. Kanski D. Acquired diseases of macular area and states connected with them // Clinical ophthalmology: Systemized approach/ Edited by V.P.Erichev.– W.: Elsevier Urban & Partner, 2009. — P. 629.

3. Libman Ye.S., Tolmachev R.A., Shakhova Ye.V. Epidemical characteristic of disability as a result of basic forms of maculopathy// Materials of II Russian seminar "Macular", "round table"/ Edited by Yu.A.Ivanishko. — Rostov on Don, 2006. — P. 15-22.

4. Libman Ye.S., Shakhova Ye.V. State and dynamics of blindness and disability as a result of visual organ pathology in Russia// Theses of reports of VII congress of ophthalmologists of Russia. — М., 2000. — Vol. 2. — P. 209-215.

5. Tishchenko O.E. Pathological retina neovascularisation: modern treatment methods, perspectives// Ophthalmosurgery. — 2010. — №4. — P. 34-39.

6. Bhutto I.A., McLeod D.S., Hasegawa T. et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration// Exp. Eye Res. — 2006. — V. 82, №1. — P. 99-110.

7. Das A., McGuire P.G. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition// Progress in Retinal and Eye Research. — 2003. — V. 22, №– P. 721-748.

8. Dawson D.W., Volpert O.V., Gillis P. et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis// Science. — 1999. — V. 285. — P. 245-248.

9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress// Endocr. Rev. — 2004. — V. 25. — P. 581-611.

10. Funk M., Karl D., Georgopoulos M. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab// Ophthalmol. — 2009. — V. 116, №12. — P. 2393-2399.

11. National Eye Institute. Comparison of AMD Treatment Trials (CATT): Lucentis-Avastin Trial. A multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD). Available at http://www.nei.nih.gov/CATT/. Accessed July 20, 2011.

12. Tezel T.H., Bora N.S., Kaplan H.J. Pathogenesis of age-related macular degeneration// Trends. Mol. Med. — 2004. — V. 10. — P. 417-420.

13. The CATT Research Group. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration// N. Engl. J. Med. — 2011. — V. 364. — P. 1897-1908.

14. Wilson P.W., D'Agostino R.B., Levy D. et al. Prediction of coronary heart disease using risk factor categories// Circulation. — 1998. — V. 97. — P. 1837-1847.

About this article